New immunotherapy may avoid bladder removal
The study paragraphs published in The Lancet Oncology journal reveal that a new immunotherapy is being used instead of bladder removal in patients with high-risk bladder cancer, where more than 81% of patients were able to avoid surgery two years after treatment. The therapy showed a complete response in 75% of patients, lasting over two years in about 60% of them, with generally mild side effects. This treatment contributes to preserving quality of life and reducing the need for surgeries, offering promising results in combating this aggressive type of cancer.
articleDetails.fontSize.sizeحجم النص
تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي
comments.heading